S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
US consumer confidence tumbles in September as American anxiety about the future grows
3 Household Names With RSIs That Scream Oversold
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
US consumer confidence tumbles in September as American anxiety about the future grows
3 Household Names With RSIs That Scream Oversold
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
US consumer confidence tumbles in September as American anxiety about the future grows
3 Household Names With RSIs That Scream Oversold
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
US consumer confidence tumbles in September as American anxiety about the future grows
3 Household Names With RSIs That Scream Oversold
NASDAQ:MESO

Mesoblast (MESO) Stock Forecast, Price & News

$1.23
+0.01 (+0.82%)
(As of 09/26/2023 ET)
Compare
Today's Range
$1.18
▼
$1.25
50-Day Range
$1.22
▼
$4.83
52-Week Range
$1.16
▼
$5.12
Volume
173,332 shs
Average Volume
202,376 shs
Market Capitalization
$200.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.13
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Mesoblast MarketRank™ Forecast

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
479.3% Upside
$7.13 Price Target
Short Interest
Healthy
0.68% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.08mentions of Mesoblast in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

224th out of 963 stocks

Biotechnology Industry

4th out of 26 stocks

See Top Rated MarketRank™ Stocks Here

MESO stock logo

About Mesoblast (NASDAQ:MESO) Stock

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

MESO Price History

MESO Stock News Headlines

September 26, 2023 | finance.yahoo.com
Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee
September 25, 2023 | americanbankingnews.com
Mesoblast Limited (NASDAQ:MESO) Given Consensus Recommendation of "Hold" by Brokerages
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
September 23, 2023 | americanbankingnews.com
Cantor Fitzgerald Reiterates "Overweight" Rating for Mesoblast (NASDAQ:MESO)
September 21, 2023 | markets.businessinsider.com
Analyst Expectations for Mesoblast's Future
September 2, 2023 | seekingalpha.com
Mesoblast Limited (MESO) Q4 2023 Earnings Call Transcript
September 1, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Cooper Co (COO) and Mesoblast (MESO)
August 31, 2023 | markets.businessinsider.com
William Blair Reaffirms Their Hold Rating on Mesoblast (MESO)
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
August 31, 2023 | markets.businessinsider.com
Analyst Bullish On Cell Therapy Player Mesoblast, But Cuts Price Target
August 31, 2023 | finance.yahoo.com
Mesoblast Limited (NASDAQ:MESO) Q4 2023 Earnings Call Transcript
August 30, 2023 | fool.com.au
Mesoblast share price rises as losses narrow in FY23
August 30, 2023 | finance.yahoo.com
Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023
August 25, 2023 | finance.yahoo.com
Decoding Mesoblast Ltd's Performance: A Deep Dive into the Metrics
August 25, 2023 | finance.yahoo.com
Is Mesoblast Ltd (MESO) a Hidden Value Trap? Unpacking the Risks and Rewards
August 8, 2023 | finance.yahoo.com
Why Shares of Mesoblast Are Down Monday
August 6, 2023 | msn.com
Dr Boreham’s Crucible: Oh, Mesoblast! You were the Chosen One!
August 5, 2023 | marketwatch.com
Mesoblast ADSs Plunge Premarket on Latest FDA Rejection >MESO
August 5, 2023 | markets.businessinsider.com
Mesoblast Shares Tumble As FDA Strikes Out Cell Therapy Application For Children Again, Requires Additional Trial
August 4, 2023 | marketwatch.com
ADRs End Mostly Higher, Missfresh and Mesoblast Trade Actively
August 4, 2023 | finance.yahoo.com
Nikola's Abrupt CEO Transition, Carl Icahn Led Icahn Enterprises Cuts Dividend Payout, FDA Rejects Mesoblast's Cell Therapy For Kids: Today's Top Stories
August 4, 2023 | finance.yahoo.com
Why Shares of Mesoblast Are Plunging Friday
August 4, 2023 | afr.com
ASX closes higher but ends the week down 1pc
August 4, 2023 | finance.yahoo.com
UPDATE 1-Mesoblast shares tank after US FDA rejects cell therapy for children
August 3, 2023 | au.finance.yahoo.com
MESO - Mesoblast Limited
August 2, 2023 | fool.com.au
Is no FDA news bad news for Mesoblast shares?
August 2, 2023 | msn.com
Mesoblast Ltd - ADR (MESO) Price Target Increased by 13.98% to 4.64
See More Headlines
Receive MESO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

MESO Company Calendar

Last Earnings
8/30/2023
Today
9/27/2023
Next Earnings (Estimated)
11/28/2023
Fiscal Year End
6/30/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MESO
Previous Symbol
OTCMKTS:MBLTY
CUSIP
N/A
CIK
1345099
Web
www.mesoblast.com
Phone
(139) 639-6036
Fax
61-3-9639-6030
Employees
83
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.13
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+479.3%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-81,890,000.00
Net Margins
-1,061.43%
Pretax Margin
-1,094.53%
Return on Equity
-16.32%
Return on Assets
-12.26%

Debt

Debt-to-Equity Ratio
0.20
Current Ratio
1.95
Quick Ratio
1.95

Sales & Book Value

Annual Sales
$7.50 million
Price / Sales
26.71
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.08 per share
Price / Book
0.40

Miscellaneous

Outstanding Shares
162,840,000
Free Float
132,227,000
Market Cap
$200.29 million
Optionable
Optionable
Beta
3.32
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Silviu Itescu FACP (Age 66)
    FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director
    Comp: $908.33k
  • Dr. Eric A. Rose M.D. (Age 72)
    Chief Medical Officer & Exec. Director
    Comp: $365.12k
  • Dr. Philip R. Krause M.B.A.
    M.D., M.S., Strategic Advisor & Director
  • Mr. Andrew Chaponnel B.Com.
    Interim Chief Fin. Officer
  • Ms. Dagmar Rosa-Bjorkeson M.B.A. (Age 59)
    M.S., Chief Operating Officer
  • Mr. Peter T. Howard B.Sc. (Age 55)
    L.L.B., BSc, LLB (Hons), Gen. Counsel & Corp. Exec.
  • Mr. Roger D. Brown BA
    Head of Spinal Orthopedic Disorders
  • Mr. Michael Schuster M.B.A. (Age 46)
    MS, BSc, MBA, Head of Pharma Partnering
  • Ms. Geraldine Storton B.Sc.
    M.B.A., Bsc, MMS, MBA, Head of Regulatory Affairs & Quality Management
  • Mr. Justin Horst B.S.
    Head of Manufacturing

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













MESO Stock - Frequently Asked Questions

Should I buy or sell Mesoblast stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MESO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares.
View MESO analyst ratings or view top-rated stocks.

What is Mesoblast's stock price forecast for 2023?

6 equities research analysts have issued 1-year price objectives for Mesoblast's shares. Their MESO share price forecasts range from $1.50 to $17.00. On average, they expect the company's share price to reach $7.13 in the next twelve months. This suggests a possible upside of 479.3% from the stock's current price.
View analysts price targets for MESO or view top-rated stocks among Wall Street analysts.

How have MESO shares performed in 2023?

Mesoblast's stock was trading at $2.91 at the start of the year. Since then, MESO stock has decreased by 57.7% and is now trading at $1.23.
View the best growth stocks for 2023 here.

When is Mesoblast's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 28th 2023.
View our MESO earnings forecast.

How were Mesoblast's earnings last quarter?

Mesoblast Limited (NASDAQ:MESO) released its quarterly earnings data on Wednesday, August, 30th. The company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.03. The business earned $2.14 million during the quarter, compared to analyst estimates of $2 million. Mesoblast had a negative net margin of 1,061.43% and a negative trailing twelve-month return on equity of 16.32%.

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Novavax (NVAX), Micron Technology (MU), Vaxart (VXRT) and AbbVie (ABBV).

When did Mesoblast IPO?

(MESO) raised $69 million in an initial public offering on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

What is Mesoblast's stock symbol?

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

Who are Mesoblast's major shareholders?

Mesoblast's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (0.09%), Lazari Capital Management Inc. (0.05%), Wells Fargo & Company MN (0.03%), Citadel Advisors LLC (0.00%), Merit Financial Group LLC (0.01%) and Creative Planning (0.01%).

How do I buy shares of Mesoblast?

Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mesoblast's stock price today?

One share of MESO stock can currently be purchased for approximately $1.23.

How much money does Mesoblast make?

Mesoblast (NASDAQ:MESO) has a market capitalization of $200.29 million and generates $7.50 million in revenue each year. The company earns $-81,890,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

How can I contact Mesoblast?

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The official website for the company is www.mesoblast.com. The company can be reached via phone at (139) 639-6036, via email at schond.greenway@mesoblast.com, or via fax at 61-3-9639-6030.

This page (NASDAQ:MESO) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -